Status:
COMPLETED
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
Lead Sponsor:
GlaxoSmithKline
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of multiple sclerosis (MS).
- Expanded Disability Status Score 0 - 6.5.
- One or more relapse of MS in previous 12 months.
- Currently not taking any medications for MS (apart from those used to treat symptoms).
- Exclusion criteria:
- Patients with significantly abnormal laboratory tests or electrocardiogram (ECG) results.
- Subjects who cannot have MRI scans.
- Women who are pregnant, breast feeding or planning to become pregnant during the study.
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
261 Patients enrolled
Trial Details
Trial ID
NCT00097331
Start Date
September 1 2004
End Date
July 1 2006
Last Update
April 13 2015
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Brussels, Belgium, 1200
2
GSK Investigational Site
Fraiture En Condroz, Belgium, 4557
3
GSK Investigational Site
Hamburg, Hamburg, Germany, 20099
4
GSK Investigational Site
Hamburg, Hamburg, Germany, 22087